Reviva Q2 net loss $12.4M; cash $11.2M; Phase 3 schizophrenia data due Oct 2023

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss of $12.4M ($0.55 per share) for Q2 2023 vs $5.3M ($0.29) a year ago.
Cash $11.2M as of June 30, 2023, down from $18.5M at Dec 2022; runway into Q4 2023.
Topline data for pivotal Phase 3 RECOVER trial of brilaroxazine in schizophrenia expected October 2023.
Enrollment near completion (~400 patients); 1-year OLE study completion expected Q3 2024.
May initiate Phase 2a studies in bipolar, MDD, ADHD in H2 2023 subject to additional financing.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported six months ended June 30, 2023 results: net income net loss of approximately $19.0 million, EPS ($0.86) per share.

Period: six months ended June 30, 2023
Net income: net loss of approximately $19.0 million
EPS: ($0.86) per share
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $19.0 million, or ($0.86) per share, for the six months ended June 30, 2023, compared to a net loss of approximately $12.7 million, or ($0.69) per share, for the same period in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported second quarter ended June 30, 2023 results: net income net loss of approximately $12.4 million, EPS ($0.55) per share.

Period: second quarter ended June 30, 2023
Net income: net loss of approximately $12.4 million
EPS: ($0.55) per share
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $12.4 million, or ($0.55) per share, for the three months ended June 30, 2023, compared to a net loss of approximately $5.3 million, or ($0.29) per share, for the same period in 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-023680

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.